SPYGLASS PHARMA INC SHS (SGP)
Health Care · Clinical-stage drug delivery biotech / ophthalmology · NASDAQ
A clinical-stage biotech company developing a sustained-release drug delivery system for intraocular lenses to treat glaucoma and other eye conditions.
What SPYGLASS PHARMA INC SHS does
Spyglass Pharma is a late-stage biopharmaceutical company focused on developing innovative drug delivery systems. The company's lead product candidate is the Bimatoprost Drug Pad-IOL System (BIM-IOL System), currently in clinical trials. The company has no approved products for commercial sale and generates no revenue to date.
Themes: ["ophthalmology / eye care"]
Fundamentals
- Price$20.07 as of 2026-07-09 close
- Market cap$684M as of 2026-07-10
- 1-year return-22.5% as of 2026-07-09 close
- ROE-75.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.57 as of 2026-07-10
Key risks (from latest filing)
["No approved products or revenue; business entirely dependent on successful clinical development and FDA approval of the BIM-IOL System"]
Competitors & peers
- Allergan (AbbVie subsidiary)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.